Dennis M. Bierle

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Raymund R. Razonable, Colin Pawlowski, John C. O’Horo et al. · EClinicalMedicine · 2021 · 134 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh, Lindsey M. Philpot, Dennis M. Bierle et al. · The Journal of Infectious Diseases · 2021 · 102 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +10

The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome

Ravindra Ganesh, Stephanie L. Grach, Aditya Ghosh et al. · Mayo Clinic Proceedings · 2022 · 95 citations · Full text

Veterinary Medicine, Immunology, Internal Medicine +11

Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study

Liewei Wang, Steven E. Scherer, Suzette J. Bielinski et al. · Genetics in Medicine · 2022 · 68 citations · Full text

Medicine, Genetics, Pharmacology +16

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar, Elena Beam, John C. O’Horo et al. · Open Forum Infectious Diseases · 2021 · 67 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17